Baka, Z., Godier, C., Mallick, A., Gribova, V., Quilès, F., Francius, G., Burgain, J., Gaiani, C., Scher, J., Gaffet, É., Alem, H., and Gaffet, Eric
3D bio-printing of living systems for food industries and medical applicationsZ. Baka, C. Godier, A. Mallick, V. Gribova, F. Quilès, G. Francius, J. Burgain, C. Gaiani, J. Scher, É. Gaffet, H. AlemNano in Bio 202230 Mai au 5 Juin 2002, Le Gosier Guadeloupehttps://nanoinbio2022.sciencesconf.org/3D bioprinting is considered as a promising technology to build living-like models. 3D constructs containing different cell types can be generated which is crucial to simulate the heterogeneity and complexity of the human cells microenvironment. As, 3D bioprinting is a computer assisted process that generates 3D structures with a controlled architecture and a high reproducibility, it makes it an interesting alternative to other cell culture approach. This presentation will then merge different works that we are conducting in collaboration with interdisciplinary teams to bring a new approach through the development of an innovative approach-based 3D bio-printing to lead to 3D structures that can be used for food industries or cancer therapies. In one hand, we will present our 3D bio-printing process able to lead efficiently to the production of the encapsulated bacteria. Each capsule contains at least 108 CFU/ml (figure 1). The bacteria in the capsules were viable up to seven days and can survived the harsh gastrointestinal fluid environment in vitro. This bioprinting method for encapsulating probiotic bacteria for their specific delivery in the gut can than become a revolutionary method for industrial applications. In another hand 3D structures were obtained to mimic the ovarian cancer for further application in cancer on chip devices by their implementation in microfluidic device. To get closer to the cancer tissue structure, ovarian cancer cells (SKOV-3) were bio-printed with cancer-associated fibroblasts (CAFs) to create the stroma cells. The hydrogel composition was first optimized to ensure good printability at 37°C while applying minimal extrusion pressure. The tumor model was then printed and cell viability was assessed using different technics including Live-Dead assay, WST1 assay and Alamar-Blue assay. Annexin V/PI assay and flow cytometry were also performed to quantify the apoptotic cells within the bioprinted structures. We have shown that the tumor-like model can be maintained alive up to 7 days and its transfer in a high-throughput microfluidic system was achieved. This work aims then to present the strength of 3D bio-printing process to lead to model structure that can be used in different field as foods or pharmaceutic industries.